Enzo Biochem (NYSE:ENZ) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZGet Rating) in a note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, TheStreet cut Enzo Biochem from a “c-” rating to a “d+” rating in a research note on Tuesday, May 17th.

Shares of ENZ stock opened at $2.19 on Tuesday. The stock has a market cap of $106.70 million, a price-to-earnings ratio of -16.85 and a beta of 0.81. The stock has a 50-day moving average of $2.47 and a 200-day moving average of $2.95. The company has a current ratio of 2.52, a quick ratio of 1.92 and a debt-to-equity ratio of 0.07. Enzo Biochem has a 1-year low of $2.09 and a 1-year high of $4.15.

In other news, Director Bradley Louis Radoff purchased 50,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The shares were acquired at an average price of $2.21 per share, for a total transaction of $110,500.00. Following the completion of the acquisition, the director now owns 3,987,163 shares in the company, valued at $8,811,630.23. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have purchased 58,100 shares of company stock valued at $128,099 in the last ninety days. 17.40% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the business. Fuller & Thaler Asset Management Inc. lifted its holdings in Enzo Biochem by 0.5% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 946,285 shares of the medical research company’s stock worth $3,038,000 after acquiring an additional 4,525 shares during the period. Bank of New York Mellon Corp lifted its holdings in Enzo Biochem by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 90,158 shares of the medical research company’s stock worth $261,000 after acquiring an additional 5,328 shares during the period. Morgan Stanley lifted its holdings in Enzo Biochem by 66.9% during the second quarter. Morgan Stanley now owns 13,551 shares of the medical research company’s stock worth $43,000 after acquiring an additional 5,432 shares during the period. BlackRock Inc. lifted its holdings in Enzo Biochem by 0.5% during the first quarter. BlackRock Inc. now owns 1,540,591 shares of the medical research company’s stock worth $4,468,000 after acquiring an additional 7,420 shares during the period. Finally, Northern Trust Corp lifted its holdings in Enzo Biochem by 7.0% during the fourth quarter. Northern Trust Corp now owns 114,523 shares of the medical research company’s stock worth $367,000 after acquiring an additional 7,462 shares during the period. Institutional investors and hedge funds own 59.64% of the company’s stock.

About Enzo Biochem (Get Rating)

Enzo Biochem, Inc, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.